Pumping up product pipeline is AstraZeneca CEO’s “No. 1 priority”

Share this article:
AstraZeneca CEO David Brennan has made strengthening the UK drug firm’s pipeline his top goal, despite strong growth of key products during 2005. “The output from our discovery organization has grown and new medicines from both our own and external research have entered late-stage development, including those from recent transactions,” Brennan told investors yesterday, according to a report on WSJ.com. “However, we will do more to further strengthen our product pipeline, and this is my number one priority.” Earlier this month, AstraZeneca lost a court case over two Toprol-XL patents in generic challenges from KV Pharmaceutical, Andrx Corp. and Eon Labs, a unit of Novartis. AstraZeneca said it would appeal the decisions. Sales for Toprol-XL in the US in 2005 were approximately $1.3 billion. AstraZeneca reported a 32% rise in fourth-quarter net profit, with full-year net profit rising 25%.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.